Macrolides and associated antibiotics based on similar mechanism of action like lincosamides in malaria by Tiphaine Gaillard et al.
Gaillard et al. Malar J  (2016) 15:85 
DOI 10.1186/s12936-016-1114-z
REVIEW
Macrolides and associated antibiotics 
based on similar mechanism of action 
like lincosamides in malaria
Tiphaine Gaillard1,2,3, Jérôme Dormoi1,2,4, Marylin Madamet2,5,6 and Bruno Pradines1,2,4,6*
Abstract 
Malaria, a parasite vector-borne disease, is one of the biggest health threats in tropical regions, despite the availability 
of malaria chemoprophylaxis. The emergence and rapid extension of Plasmodium falciparum resistance to various 
anti-malarial drugs has gradually limited the potential malaria therapeutics available to clinicians. In this context, mac-
rolides and associated antibiotics based on similar mechanism of action like lincosamides constitute an interesting 
alternative in the treatment of malaria. These molecules, whose action spectrum is similar to that of tetracyclines, are 
typically administered to children and pregnant women. Recent studies have examined the effects of azithromycin 
and the lincosamide clindamycin, on isolates from different continents. Azithromycin and clindamycin are effective 
and well tolerated in the treatment of uncomplicated malaria in combination with quinine. This literature review 
assesses the roles of macrolides and lincosamides in the prophylaxis and treatment of malaria.
Keywords: Antibiotics, Antimalarial drug, Malaria, Plasmodium falciparum, Macrolides, Lincosamides, Treatment, 
Resistance
© 2016 Gaillard et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Malaria, a parasite vector-borne disease, is one of the 
largest health threats in tropical regions, despite the 
availability of malaria chemoprophylaxis and the use of 
repellents and insecticide-treated nets [1]. The prophy-
laxis and chemotherapy of malaria remains a major area 
of malaria research, and new molecules are constantly 
being developed prior to the emergence of resistant para-
site strains. The use of anti-malarial drugs is conditioned 
based on the level of resistance of Plasmodium falcipa-
rum in endemic areas and the contraindications, clinical 
tolerance and financial costs of these drugs. Among the 
compounds potentially used against Plasmodium, antibi-
otics have been examined in vitro or in vivo.
After tetracyclines, the second family of potential anti-
biotics in the fight against Plasmodium includes mac-
rolides and macrolide derivatives, a class of compounds 
with 14-20 membered macrolactone ring. Another class 
of antibiotics, licosamides whose chemical structure dif-
fers from the macrolides, are associated with the mac-
rolides based on similar mechanism of action. Recent 
studies have examined the effects of the macrolide 
azithromycin and the lincosamide clindamycin, on iso-
lates from different continents [2–4]. These molecules, 
whose action spectrum is similar to that of tetracyclines, 
are typically administered to children and pregnant 
women [5–11].
This literature review assesses the roles of macrolides 
and macrolide derivatives in the prophylaxis and treat-
ment of malaria.
Classification of macrolides and associated antibiotics 
based on similar mechanism of action like lincosamides
The macrolide family comprises lincosamides and strep-
togramines, referred to as the MLSB group. These anti-
biotics, with a distinct chemical structure, are classified 
in the same group based on comparable activity spectra 
and identical functional mechanism, based on the inhibi-
tion of protein synthesis. These antibiotics, with limited 
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activity spectra, are particularly active against the intra-
cellular germs and are currently administered to children 
and pregnant women [5–11], conferring a notable advan-
tage compared with tetracyclines. Certain antibiotics of 
this family are useful as anti-malarial substances.
The classification of macrolides is based on the num-
ber of carbon links, which distinguishes macrolides 
with 14 atoms from 15- or 16-membered macrolides. 
The 14-membered erythromycin is the oldest molecule 
(1952); all second-generation macrolides: roxithromycin, 
clarithromycin and dirithromycin [12] are products of 
hemisynthesis and derived from erythromycin. The only 
azalide with 15 carbon atoms is azithromycin, produced 
through the introduction of a nitrogen atom inserted 
into the macrolide nucleus at C10. This modification has 
improved the penetration of drugs into macrophages, 
fibroblasts and polymorphonuclear neutrophils, facili-
tating increased accumulation within acidified vacuoles 
and extending the half-life [4]. It has also improved activ-
ity against Gram-negative bacteria and other pathogens 
from parasitic infections [13]. The antibiotics with 16 
carbon links are spiramycin and josamycin. Chemical 
modifications are constantly being developed to optimize 
this family [14].
Lincosamides are antibiotics associated with the mac-
rolides based on a similar action spectrum, although 
the structure of these compounds differs. Lincomycin 
is a sugar isolated in 1962 from fermentation through 
Streptomyces lincolnensis. Substitution of the C7 bear-
ing a hydroxyl function with a chlorine atom generated a 
semi-synthetic derivative, such as 7-chloro-7-deoxy-lin-
comycin or clindamycin, with a higher antibiotic activity 
and digestive absorption. Clinical trials have shown the 
efficacity, safety and practicability of the treatment of P. 
falciparum malaria with clindamycin [2].
Pharmacological properties
Macrolides exhibit poor digestive absorption of less than 
60 %, and this effect is strongly influenced by food. The 
half-life of these drugs is variable, from a short half-life 
for erythromycin (2 h) and clarithromycin (4 h) to long 
half-life for azithromycin (68 h) [3]. Efforts for develop-
ment of molecules of this family were first employed to 
improve pharmacological properties, but not antimicro-
bial activities.
With the exception of cerebrospinal fluid and brain, 
macrolides show excellent tissue distribution in tissues, 
such as bone and liver. Erythromycin and clarithromy-
cin are highly metabolized in the liver through interac-
tions with cytochrome P450 CYP3A4, which has been 
implicated in many drug interactions. The elimination of 
macrolide and macrolide derivatives is primarily biliary. 
Indeed, liver failure severely disrupts pharmacokinetics. 
Concerning azithromycin, mild renal dysfunction and 
mild-to-moderate hepatic dysfunction do not signifi-
cantly affect excretion.
Azithromycin is a slightly metabolized molecule, with 
37  % bioavailability after oral administration [15]. It is 
known to have a large volume of distribution, achieving 
high tissue concentrations. It accumulates in hepatic, 
renal, pulmonary and splenic tissues and gradually 
leaches into the bloodstream over a period of 1  week 
[16]. It also accumulates within fibroblastes and phago-
cytic lysosomes; these cells may serve as a reservoir for 
slow release of the drug [17]. Compared with older gen-
eration macrolides, it is more stable in acidic media and 
has a longer half-life, allowing for once a day [18]. Indeed, 
following a standard 500 mg oral dose, peak plasma con-
centrations are attained with a Tmax of 2–4 h; the plasma 
half-life of azithromycin is approximately 70 h following 
oral formulation [18].
Among lincosamides, clindamycin has a 90 % digestive 
absorption. Unlike lincomycin, clindamycin absorption is 
not reduced, but only delayed, through food intake. Char-
acterized by slow but thorough anti-malarial activity, 
clindamycin presents a remarkably short plasma half-life 
(2–4  h) [7]. Lincosamides exhibit good tissue penetra-
tion, and contrary to macrolides, pass the blood–brain 
barrier. Clindamycin metabolism occurs in the liver, with 
elimination and high bile concentration. In hepatic insuf-
ficiency, the half-life can be extended twice and doses 
should be reduced accordingly. With respect to the effect 
on Plasmodium, clindamycin slowly accumulates in para-
sites [6].
Tolerance
Macrolides are generally well tolerated; moreover, 
they exhibit a good safety profile in children and preg-
nant women [14]. The adverse events most frequently 
reported are gastrointestinal disorders: nausea, vomit-
ing, and episgastralgia associated with the administered 
dose. Other side effects, such as neurosensory in the type 
of headache and dizziness disorders, skin allergies and 
rare cases of cholestatic hepatitis, have been reported, 
but these effects are rare. The “old” molecules typically 
present more side effects than the newer molecules. 
Macrolides are largely a problem of drug interference, 
reflecting the role of cytochrome [19]. Notably, although 
the risk of drug interactions is high, the risk of interac-
tions with new molecules is much less important.
Drug interactions are less frequently observed with lin-
cosamides than with macrolides. The oral forms of lin-
cosamides exhibit a more irritative effect (esophagitis) 
than the parenteral forms (chemically induced phlebitis). 
Systemic reactions, including allergies, skin reactions and 
anaphylactic shock, have been reported. Diarrhoea and 
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digestive disorders primarily occur with the oral forms 
[2]. Moreover, the appearance of pseudomembranous 
colitis resulting from Clostridium difficile toxin selec-
tion is characterized by profuse watery diarrhoea, fever, 
and occasional bleeding, requiring the discontinuation 
of treatment [20]. Moreover, rapid intravenous admin-
istration might reflect the electrocardiographic changes 
and even collapse of cardiac arrest observed in response 
to lincosamide treatments [21]. Haematologic disorders, 
such as leukopenia, neutropenia, and thrombocytope-
nia have been reported. Gastrointestinal disorders are 
frequently reported in patients receiving azithromycin. 
Doses of azithromycin between 500 and 2000  mg have 
been used in all trimesters of human pregnancy for the 
treatment of upper and lower respiratory tract infections, 
skin diseases, and infections with Chlamydia trachoma-
tis, Mycoplasma and group B streptococci among women 
allergic to other antibiotics [4]. Nevertheless, azithromy-
cin delays cardiac polarization [21, 22], although prelimi-
nary studies concerning the combination of azithromycin 
with chloroquine for QT prolongation indicate that car-
diac instability is not increased under this combination 
[23].
Mechanism of antiplasmodial action
In bacteria, macrolides inhibit the synthesis of cell pro-
teins through binding to the 50S subunit of the ribo-
some. The inhibition of protein synthesis through the 
inhibition of transpeptidation explains the postantibiotic 
effects of this drug, measured after 3–4 h. The macrolide 
antibacterial spectrum is similar to that of erythromy-
cin. This spectrum is limited to Gram-positive bacteria, 
and Gram-negative bacilli remain impermeable to these 
molecules; however, because of the intracellular con-
centration of these drugs, macrolides are active against 
intracellular bacteria development [24]. New macrolide 
compounds, including the azalide azithromycin, and 
lincosamides present more or less broader antibacterial 
activity than erythromycin; the lincosamide clindamycin 
remains of particular interest as therapy for some para-
sitic infections [13]. Anti-malarial properties occur by 
targeting the bacterium-derived translational machinery 
in the relict plastid, apicoplast, present in Plasmodium 
spp. [14]. This organelle is limited by four membranes 
and located within parasitic cells; it contains a 35 kb cir-
cular DNA allowing [16] replication, RNA transcription 
and RNA–protein translation [25].
The macrolide antibiotic azithromycin exhibits the 
best antiplasmodial properties. This molecule targets 
the 70S ribosomal subunit from the apical complex [16], 
comprising 50S and 30S subunits. Once fixed, mac-
rolide prevents the synthesis of the polypeptide, which 
is subsequently prematurely released [4]. The synthesis 
of a nonfunctional apicoplast, resulting from exposure 
to azithromycin, is at the origin of the delayed effect of 
the molecule. Indeed, parasites treated during first 48 h 
life cycle show non obvious defect from the loss of api-
coplast-encoded gene products: organelle morphology, 
genome replication protein targeting and segregation 
during cell division remain intact. Likewise, parasites 
progress normally through the different developmental 
stages, giving rise to daughter merozoites that success-
fully reinvade to establish infection of a new host cell. 
The deleterious effects of antibiotic occur in the second 
life cycle following antibiotic treatment in which the 
apicoplast genome fails to replicate [26]. Thus, similar 
to tetracyclines, the antiplasmodial action of this mac-
rolide is therefore delayed [27, 28]; this phenomenon in 
which the parasite completes a full cycle before achiev-
ing growth inhibition is referred to “delayed death” [29]. 
Delayed death is a strategy for examining whether an 
antibiotic acts on the apicoplast, and unlike antiparasitic 
molecules with immediate effects, the activity of antipar-
asitic compounds on some functions of the apicoplast is 
measurable beyond cell division. Several studies have also 
identified the immediate activity of azithromycin [30–
32], well above that of older macrolides. The mechanism 
responsible for this activity has not been elucidated [14] 
and clinical studies failed to demonstrate even equiva-
lence of 3-day treatment with azithromycin to other anti-
malarial drugs [18].
The target of clindamycin has been recently demon-
strated in Plasmodium. This drug was originally extrap-
olated from Toxoplasma gondii, frequently used as a 
model based on structural similarities [2, 33]. In T. gondii, 
clindamycin and the three major clindamycin metabo-
lites are fixed to the large subunit ribosomal RNA of 
the apicoplast [33]. Several studies have shown a lethal 
effect of clindamycin on potentiated parasites after 72 h 
of exposure [29], although the antibiotic concentrations 
were reduced 3–4 factors less than the IC50.
It has also been suggested that parasites exposed to 
clindamycin divide and invade new host cells, but at 
this point, the cells are unable to grow and eventually 
perish. These results, prior to an in-depth study of the 
apicoplast, revealed the toxicity of clindamycin on a 
structure involved in the translation of plasmodial ribo-
somal RNA into protein [34]. These findings contributed 
to the antiplasmodial action of clindamycin after 3 days 
of administration [35]. In 2005, the target of clindamycin 
was identified [36]. Clindamycin binds the 50S subunit, 
comprising ribosomal 23S, 5S and ribosomal proteins 
L4 and L22. The same mode of action was described for 
azithromycin two years later. Plasmodium falciparum 
ribosomal protein L4 (PfRpl4) has been demonstrated to 
associate with the nuclear genome-encoded P. falciparum 
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ribosomal protein L22 (PfRpl22) and the large subunit 
rRNA 23S to form the 50S ribosome polypeptide exit 
tunnel, which could be occupied by azithromycin [16].
Clinical effectiveness
Due to the short half-life of the first generation of mac-
rolides, their use for anti-malarial treatment is limited. 
The best-studied antiplasmodial molecules include 
azithromycin, for which chemical modifications signifi-
cantly increase the half-life, and clindamycin.
In this section, the clinical trials using azithromy-
cin and those using clindamycin will be successively 
discussed.
Concerning azithromycin, its antiplasmodial action 
was first described in  vitro at the beginning of the 90s 
[17, 37]. At the end of the 90s, the mass distribution of 
azithromycin through the World Health Organization 
(WHO) trachoma elimination programme was shown to 
reduce malarial parasitaemia [38]. Several studies con-
cerning the antiparasitic properties of antibiotics showed 
the delayed action of the molecule [16, 27, 28]. Only one 
clinical multicentre study of azithromycin for the treat-
ment of acute uncomplicated P. falciparum malaria was 
conducted in India on 15 participants. In this study, 
patients were randomly assigned to groups treated with 
either azithromycin or chloroquine alone, or azithro-
mycin associated with chloroquine [3]. The resolution 
of parasitaemia was inadequate with monotherapy with 
either azithromycin or chloroquine, but combination 
therapy provided substantially improved clinical and par-
asitological outcomes. The delayed resolution of parasi-
taemia and the potential adverse effects that may occur 
with effective high doses [39] confirmed that this drug 
was unsuitable for monotherapy treatment by azithromy-
cin. In addition, different associations were tested in vivo 
(Table 1).
The effects of associations, such as azithromycin–chlo-
roquine and azithromycin–quinine, were additive on 
sensitive chloroquine strains and synergistic on resistant 
strains [40]. Other associations were examined, show-
ing effectiveness, associating azithromycin with a rapidly 
acting schizonticidal compounds, such as lumefantrine 
or artemisinin [9, 41]. Two in vitro studies [40, 42] sug-
gested that the dihydroartemisinin-azithromycin com-
bination had antagonistic effects and should be avoided. 
An in  vivo study conducted in Thailand [41], a geo-
graphic area with high levels of resistance to anti-malarial 
drugs, showed that azithromycin–artesunate, even when 
administered only once daily for 3 days, and azithromy-
cin–quinine, administered three times daily, are safe and 
efficacious combination treatments for uncomplicated 
falciparum malaria. A randomized controlled trial per-
formed in Tanzanian children did not support the use 
of azithromycin–artesunate as treatment for malaria; 
indeed, the 58  % parasitological failure rate observed 
after day 28 clearly showed that this treatment could 
not be an appropriate first line treatment for malaria [9]. 
One clinical trial conducted in Bangladesh performed 
on 152 patients suggested that this combination was an 
efficacious and well-tolerated treatment for patients with 
uncomplicated falciparum malaria compared with the 
artemether–lumefantrine combination [43]. This study 
did not consider the re-emergence of parasites in the 
peripheral blood as a failure of the treatment, although 
the mean time was 31.5  ±  5  days. Moreover, these 
authors did not distinguish the study group according to 
the age of the patients and mixed children and adults for 
the data integration.
The efficacy of the azithromycin–quinine combination 
was confirmed in 2006 [44] when 100 % of the patients 
were cured through high azithromycin regimens (combi-
nation of quinine with 1000 mg of azithromycin per day 
for 5 days or 1500 mg of azithromycin for 3 days).
A longitudinal trial comparing the effects of chloro-
quine as a monotherapy or in combination with other 
drugs, including azithromycin, on children with repeated 
malaria infections in Malawi demonstrated a high effi-
cacy of the repeated administration of different regimens 
and showed a significantly higher haemoglobin concen-
tration in children in the chloroquine–azithromycin 
group. This result might reflect the prevention or treat-
ment of bacterial infections [10]. This combination, chlo-
roquine–azithromycin was recently confirmed as highly 
efficient and well tolerated in African adults [11].
Another combination treatment comprising azithro-
mycin with sulfadoxine–pyrimethamine was tested in 
pregnant women from Malawi [8]. Sulfadoxine–pyrimeth-
amine has been adopted in many sub-Saharan Africa 
countries as the drug of choice for intermittent preventive 
therapy to reduce placental malaria and low-birth weight. 
The azithromycin–sulfadoxine–pyrimethamine combi-
nation might have several advantages: first, although the 
parasite clearance rate was slow compared with sulfadox-
ine–pyrimethamine–artesunate, the rate of recrudescence 
was low and markedly similar between the two groups. 
Secondly, azithromycin has an adequate safety profile, as 
this molecule has often been used in pregnant women to 
treat STIs. In contrast, there has been concern about the 
use of artemisinin derivatives during the first trimester 
based on animal studies [45]. Thirdly, azithromycin has 
a relatively long half-life compared with artesunate. The 
azithromycin–sulfadoxine–pyrimethamine combination 
protects the longer-acting drug (sulfadoxine–pyrimeth-
amine) [8], by decreasing the probability of parasites 
encountering sub-therapeutic drug levels and promoting 
the development of resistance [46].
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Despite these results, a review from the Cochrane Col-
laboration [39] concluded that the available evidence sug-
gested that azithromycin was a weak anti-malarial with 
some appealing safety characteristics, and that azithro-
mycin’s future for the treatment of malaria did not look 
promising.
Concerning lincosamides, clindamycin is a major 
antibiotic for the treatment of anaerobic bacterial infec-
tions [47]. This drug also presents antimicrobial activity 
against Plasmodium, Toxoplasma, Babesia and Pneumo-
cystis spp. Moreover, clindamycin is the drug of choice 
for treatment against toxoplasmic chorioretinitis in new-
borns and one of the treatments recommended in the 
babesiosis with Babesia microti and B. divergens [48]. 
Associated with pyrimethamine or primaquine, clinda-
mycin is a treatment of second intention against toxo-
plasmosis and pneumocystosis [49].
The antiplasmodial indication of clindamycin was 
managed according to various therapeutic regimens. 
The effectiveness of clindamycin in monotherapy in 
this indication was initially reported in 1975 [50]. The 
WHO repeated this protocol in several studies con-
ducted on different continents, and several sightings have 
been reported (Table  2), including the effectiveness of 
clindamycin in monotherapy against malaria. This effi-
ciency is however conditioned through treatment for 
5 days, with twice-daily administration, as this molecule 
acts slowly. Clindamycin is well tolerated, and minor side 
effects have been reported during treatment. The occur-
rence of diarrhoea resulting from Clostridium difficile 
has often been reported after treatment with clindamy-
cin, and this side effect might progress to pseudomem-
branous colitis, as a result of lengthy treatment with 
antibiotics [51]. The potential problem of severe diar-
rhoea, observed in patients receiving a prolonged and 
high dose of clindamycin therapy, is not observed with a 
low dose and short duration of therapy to treat malaria 
[52]. The WHO did not ultimately recommend clindamy-
cin treatment when used alone as an anti-malarial treat-
ment, as parasite clearance might be deleterious in cases 
of significant parasitaemia in fragile subjects (children 
and pregnant woman) [2]. However, clindamycin is now 
recommended for pregnant women in the first trimes-
ter with uncomplicated malaria, in association with qui-
nine or artemisinin-based combination therapies or oral 
artesunate for 7 days.
The combination of clindamycin with other rapidly act-
ing drugs is essential for the optimization of treatment. 
Table 2 Clinical trials of clindamycin monotherapy against P. falciparum malaria
A adults, C children
Study demographic details Regimen
Year Place Reference Pop Nb Dosage Form Nb doses/d Route Nb days Efficacy (%)
1975 USA Clyde, 1975 [50] A 3 450 mg Salt 3 PO 3 100
1975 Thailand Hall, 1975 [79] A 10 450 mg Salt 3 PO 3 50
1981 Brazil Alecrim, 1981 [80] A 17 10 mg/kg Salt 2 IV 3 65
1981 Brazil Alecrim, 1981 [80] A 14 10 mg/kg Salt 2 IV + PO 7 100
1982 Brazil Alecrim, 1982 [81] A 26 10 mg/kg Salt 2 IV, PO 5 100
1982 Philippines Rivera, 1982 [82] A 24 300 mg Salt 2 IV + PO 7 100
1982 Philippines Rivera, 1982 [82] A 12 600 mg Salt 2 IV + PO 7 100
1982 Philippines Cabrera, 1982 [83] A 12 10 mg/kg Salt 2 IV + PO 7 100
1982 Philippines Cabrera, 1982 [83] A 19 20 mg/kg Salt 2 IV 3 89
1984 Columbia Restrepo, 1984 [84] A 6 20 mg/kg Salt 2 IV 3 100
1984 Columbia Restrepo, 1984 [84] A 9 10 mg/kg Salt 2 IV + PO 7 100
1984 Columbia Restrepo, 1984 [84] A 5 20 mg/kg Salt 2 IV 7 100
1984 Columbia Restrepo, 1984 [84] A 10 20 mg/kg Salt 1 IV 7 100
1985 Sudan El Wakeel, 1985 [85] A 20 5 mg/kg Salt 2 PO 5 90
1988 Brazil Meira, 1988 [86] A, C 129 10 mg/kg Salt 2 PO, IV 5–7 97
1988 Brazil Meira, 1988 [86] A, C 16 10 mg/kg Salt 1 PO, IV 5–7 50
1988 Brazil Meira, 1988 [86] A, C 35 2.5 mg/kg Salt 1 PO 5 80
1989 Brazil Kremsner, 1988 [20] A 35 5 mg/kg Base 2 PO 5 100
1990 Philippines Salazar, 1990 [87] A 31 300 mg Salt 2 PO 5 100
1990 Philippines Salazar, 1990 [87] A 10 600 mg Salt 2 PO 5 100
1993 Gabon Salazar, 1990 [87] A 38 5 mg/kg Base 2 PO 5 97
1994 East Timor Oemijati, 1994 [88] A 30 300 mg Salt 2 PO 5 100
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Clinically documented associations essentially involve the 
combination of clindamycin with quinine or chloroquine.
Quinine, showing a rapid onset and short half-life, is 
the ideal partner. In vitro studies have also shown a syn-
ergistic effect when the two molecules are associated [7, 
52]. The bioavailability of the two drugs, when co-admin-
istered, remains unchanged [53]. A methodology and sat-
isfactory post-treatment follow-up in approximately ten 
clinical trials with a wide number of patients have been 
published (Table  3) [2]. The duration of combination 
therapy remains controversial. While most studies con-
sider that the administration of quinine for at least 7 days 
and clindamycin for at least 5 days is needed, treatments 
conducted for 3  days in African studies were effective 
[52, 54]. Short-duration treatment is justified for obtain-
ing adequate compliance and fear of side effects with 
quinine. Parasite clearance has been correlated with par-
asitaemia in children treated for 4 days [55, 56]. In areas 
of multidrug resistance, such as Thailand, 5–7  days are 
needed to cure malaria.
The second well-studied combination is clindamy-
cin with chloroquine. Plasmodium falciparum is highly 
resistant to chloroquine in most malarial regions. How-
ever, this drug is still widely used and remains a first-line 
treatment in Africa. The clindamycin–chloroquine com-
bination has been studied in Gabon [52], where chlo-
roquine resistance is markedly high. Clindamycin was 
administered every 12 h for 3  days, and success rates 
ranged from 70 % in children to 97 % in adults, depending 
on the study [57]. The success rate in children was esti-
mated as 94 % with chloroquine administered at a dose of 
45 versus 25  mg/kg. Although these findings favour the 
effectiveness of the combined administration of chloro-
quine with clindamycin for 3 days, this treatment has not 
been widely adopted in practice.
Fosmidomycin, a phosphonic acid derivative, is a new 
anti-malarial drug with a novel mechanism of action 
that inhibits the synthesis of isoprenoid in P. falciparum 
and suppresses the growth of multidrug-resistant strains 
in  vitro [58]. Studies in Africa evaluating fosmidomycin 
as a monotherapeutic agent demonstrated that the drug 
is well tolerated in humans. A randomized, controlled, 
open-label study was conducted in 2003 in children to 
evaluate the efficacy and safety of treatment with fosmi-
domycin combined with clindamycin (30 and 5  mg/kg 
body weight every 12 h for 5 days, respectively) compared 
with treatment with either fosmidomycin or clindamycin 
alone. The combined treatment with the two molecules 
was superior to that with either agent alone [6].
Since 2010, the WHO advocates artemisinin-based 
combination therapy (ACT) as the mainstay in combat-
ing drug-resistant malaria in Africa [59]. To prevent 
the emergence of resistant mutants, various drugs have 
been studied in combination with artemisinin deriva-
tives, according to the underlying principle to combine 
artemisinins with drugs that have long plasma elimina-
tion half-lives. These treatments seems inappropriate 
for patients from areas with a high rate of malaria trans-
mission because of the increased risk of drug-resistant 
mutants resulting from prolonged exposure to subthera-
peutic levels of the slowly eliminated drug in the combi-
nation [7, 60, 61]. In the same way, combination therapy 
with drugs that have a rapid elimination time reduces 
the selection of resistant isolates [62]. The difficulty lies 
in choosing the ideal combination given the pharmacoki-
netic properties of the molecules used. One clinical trial 
combining artesunate with clindamycin for the treatment 
of uncomplicated P. falciparum malaria in Gabonese chil-
dren was reported in 2005 [7]. In this trial, clindamycin 
was selected based on promising results from animal 
models, in  vitro studies of P. falciparum and the use of 
sequential treatment with artesunate and clindamycin on 
Brazilian children [63]. An open-labelled, randomized, 
controlled clinical trial was performed to evaluate the 
efficacy and tolerance of oral artesunate-clindamycin 
therapy (2 and 7  mg/kg) administered twice daily for 
3  days compared with a standard quinine–clindamy-
cin regimen administered twice daily for 3 days to treat 
uncomplicated falciparum malaria in 100 children. The 
results showed that the artesunate-clindamycin combi-
nation was consistent with that of quinine–clindamycin 
with respect to the cure rates (87 versus 94 % at day 28 
of follow up). The decreased fever and parasites clearance 
were significantly shorter in the artesunate-clindamycin 
treatment group. Based on the results of this study, clin-
damycin associated with artemisinin-based combination 
therapy is a candidate for studies in areas with a high rate 
of malaria transmission.
Another in  vivo study was conducted to evaluate the 
efficacy and drug interactions of clindamycin in com-
bination with other anti-malarial drugs in populations 
from endemic areas. Some artemisinin derivatives have 
been tested on mice, such as the novel semi-synthetic 
endoperoxide artemisone [64]. This compound is synthe-
tized from dihydroartemisin in a one-step process and in 
combination with clindamycin, exhibited increased anti-
plasmodial activity, improved in vivo half-life, improved 
oral bioavailability and metabolic stability, and presented 
tolerance and no neurotoxicity in humans compared 
with artesunate. Because this drug is a good candidate, 
clinical studies must be performed to assess the effect 
of artemisone in combination with other anti-malarials. 
If macrolides and their derivatives have been considered 
as good candidates for the treatment of uncomplicated 
malaria, their pharmacokinetic properties make them 
inconsistent against malaria in monotherapy [39].
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Resistance mechanisms
Resistance to macrolides and lincosamides has been 
increasingly reported in clinical isolates of Gram-posi-
tive bacteria. One aspect of this resistance is the multi-
plicity of mechanisms and the diversity in phenotypic 
expression of several of these mechanisms. Bacteria resist 
macrolides and lincosamides antibiotics in three ways, 
including target-site modification through methylation 
or mutation to prevent the binding of the antibiotics to 
ribosomal targets, which confers broad-spectrum resist-
ance to macrolides and lincosamides, antibiotic efflux, 
and drug inactivation. However, these last two mecha-
nisms only affect some molecules [65].
Ribosomal methylation remains the most widespread 
mechanism of resistance. Resistance to erythromycin has 
been observed in staphylococci since 1956. Biochemi-
cal studies indicated that resistance resulted from the 
methylation of the ribosomal target of the antibiotics, 
leading to cross-resistance to macrolides, lincosamides 
and streptogramin B. Subsequently, the MLSB pheno-
type encoded by a variety of erm (erythromycin ribo-
some methylase) genes was reported in a large number of 
microorganisms [66]. Erm proteins facilitate the dimeth-
ylation of a single adenine in nascent 23S rRNA, as a part 
of the large (50S) ribosomal subunit [67]. A wide range 
of microorganisms, including spirochetes and anaerobes, 
which express Erm methylases, are targets for macrolides 
and lincosamides. The target mutation was first described 
for Escherichia coli mutants highly resistant to erythro-
mycin. Mutations in domain V of rRNA were identified 
in 2001 [68]. Depending on the species, bacteria possess 
1 to several rrn operons encoding 23S rRNA. In general, 
these mutations were observed in pathogens with 1 or 2 
rrn copies, often with each copy carrying the mutation. 
This mechanism is responsible for the clarithromycin 
resistance of some Mycobacterium avium, Helicobacter 
pylori and Treponema pallidum strains [65]. Mutations in 
ribosomal proteins L4 and L22, which confer erythromy-
cin resistance, have been documented for Streptococcus 
pneumoniae.
The antibiotic efflux is the second mechanism of resist-
ance described for macrolides. In Gram-negative bac-
teria, chromosomally encoded pumps contribute to 
intrinsic resistance to hydrophobic compounds, such as 
macrolides [66, 69]. These pumps often belong to a fam-
ily comprising proteins with 12 membrane-spanning 
regions [70]. In Gram-positive organisms, the acquisition 
of macrolide resistance through active efflux is mediated 
through two classes of pumps: the ATP-binding-cassette 
(ABC) transporter superfamily and the major facilitator 
superfamily (MFS) [71]. The genes encoding these pumps 
are variable depending on the bacterial genus. The efflux 
Table 3 Clinical trials of clindamycin plus other drug against P. falciparum malaria
Randomized controlled trial
Only trials with adequate dosing, i.e. clindamycin given at least twice daily are mentioned in this table
Pop population, A adult, C children, P pregnant women
a C chloroquine, Q quinine, F fosmidomycin, A artesunate
Study demographic details Regimen Efficacy (%)
Year Place Reference Pop Nb Clindamycin Other drug Route Days
Dosage Form Nb doses/d Druga Dosage/d Nb doses/d
1974 USA Miller, 1973 [53] A 5 PO 3 100
1975 USA Clyde, 1975 [50] A 5 450 mg Salt 3 Q 560 mg 3 PO 3 60
1975 USA Clyde, 1975 [50] A 2 600 mg Salt 1 Q 560 mg 3 PO 3 50
1975 Thailand Hall, 1975 [79] A 4 450 mg Salt 3 Q 540 mg 3 PO 3 100
1975 Thailand Hall, 1975 [79] A 5 150 mg Salt 3 Q 270 mg 3 PO 3 60
1987 Brazil Kremsner, 1988 [20] A 40 15 mg/kg Base 2 Q 10 mg/kg 2 PO 3 90
1992 Gabon Kremsner, 1994 [52] C 34 5 mg/kg Base 2 Q 12 mg/kg 2 PO 3 88
1993 Gabon Metzger, 1995 [89] C 33 5 mg/kg Base 2 CQ 25 mg/kg 3 PO 3 70
1995 Gabon Kremsner, 1995 [90] C 50 5 mg/kg Base 3 Q 8 mg/kg 3 IV 4 96
1995 Gabon Metzger, 1995 [54] A 40 5 mg/kg Base 2 Q 12 mg/kg 2 PO 3 92
1996 France Parola, 2001 [91] A 53 5 mg/kg Salt 3 Q 8 mg/kg 3 IV 3 100
1997 Gabon Vaillant, 1997 [57] C 161 8 mg/kg Salt 2 Q 8 mg/kg 2 PO 3 97
2000 Thailand Pukrittayakamee [92] A 68 5 mg/kg Base 4 Q 8 mg/kg 3 PO 7 100
2001 Thailand McGready, 2001 [5] P 65 5 mg/kg Salt 3 Q 8 mg/kg 3 PO 7 100
2004 Gabon Bormann, 2004 [6] C 12 10 mg/kg Salt 2 F 60 mg/kg 2 PO 5 100
2004 Gabon Ramharter, 2005 [7] C 100 7 mg/kg Salt 2 A 2 mg/kg 2 PO 3 87
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system is multicomponent in nature, involving plasmidic 
and chromosomal genes that constitute a fully opera-
tional efflux pump with specificity for 14- and 15-mem-
bered macrolides and type B streptogramines (the MSB 
phenotype).
The last mechanism of bacterial resistance is the inac-
tivation of antibiotics. Esterases and phosphotransferases 
reported in enterobacteria confer resistance to erythro-
mycin and other 14- and 15-membered macrolides, but 
not to lincosamides. These resistance mechanisms have 
not been considered of major clinical importance because 
enterobacteria are not targets for macrolides. Some clini-
cal isolates of S. aureus produce phosphotransferases, but 
this event remains rare [72–74]. In pathogenic microor-
ganisms, the impact of the three mechanisms is unequal 
in terms of incidence and clinical implications.
Concerning Plasmodium spp., if prophylactic failures 
have been observed neither for both the two molecules, 
in  vivo resistance has not been demonstrated nor for 
clindamycin or azithromycin. However, experimental 
models of resistant Plasmodium have been developed 
under selection pressure: strains of P. berghei resistant 
to clindamycin were described in two studies performed 
in the 1970s [75, 76]; P. falciparum isolates resistant to 
azithromycin have been developed later [16], but mecha-
nisms underlying the resistance of Plasmodium against 
molecules from the MLSB family were not clearly iden-
tified. Mutations on A1875 (corresponding to the E. coli 
A2058 nucleotide in the peptidyltransferase centre of 
domain V) and A706 (corresponding to the E. coli A754 
in domain II) in the P. falciparum apicoplast LSU rRNA 
(bearing 70 % identity to the 23S rRNA [77] did not con-
fer in  vitro resistance to macrolide in P. falciparum as 
observed in bacterial species [16]. The G1878 mutation, 
which confers resistance to clindamycin and azithro-
mycin in Toxoplasma gondii [33], remained unchanged 
in azithromycin-resistant P. falciparum parasites [16]. 
A mutation was identified at nucleotide position 438 
(T438C) after azithromycin-resistance selection. A single 
point mutation was also identified at codon 76 (G76 V) in 
the Pfrpl4 gene in azithromycin-resistant parasites.
Conclusions
The emergence and rapid extension of P. falciparum 
resistance to principal anti-malarial drugs necessitates 
the search for new molecules. Macrolides and their deriv-
atives have been considered as good candidates but the 
design of more effective structural analogues is required, 
essentially to improve pharmacokinetic properties. The 
synthesis of single compounds that yields both fast- and 
slow-acting profiles by targeting different parasite meta-
bolic processes is being developed to achieve effective 
molecules and mitigate parasite resistance.
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